Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1098-1107

  Raponi, Sara ^a   Stefania De Propris, Maria ^a   Intoppa, Stefania ^a   Laura Milani, Maria ^a   Vitale, Antonella ^a   Elia, Loredana ^a   Perbellini, Omar ^b   Pizzolo, Giovanni ^b   Foà, Robin ^a   Guarini, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Acute lymphoid leukemia (ALL); antibody binding capacity (ABC); antigen expression; mean fluorescence intensity (MFI); monoclonal antibody therapy

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD33 ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CHILD; CORRELATION ANALYSIS; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; YOUNG ADULT;

EID: 79957450612     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.559668     Document Type: Article

References (34)

1. Rowe JM, Buck G, Burnett AK, et al.; ECOG MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ ECOG E2993. Blood 2005;106:3760-3767. (Pubitemid 41739010)
2. Pui CH. Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 2009;27:5121-5123.
3. Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult lymphoblastic leukemia. Curr Opin Oncol 2006;18: 652-659. (Pubitemid 44427643)
4. Foa R, Vitale A. Towards an integrated classification of adult acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002;6:181-199.
5. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 2002;6:114-141.
6. Benè MC. Immunophenotyping of acute leukemias. Immunol Lett 2005;98:9-21.
7. Thomas DA, OBrien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009;113:6330-6337.
8. Kuriakose P. Targeted therapy for hematologic malignancies. Cancer 2005;12:82-90. (Pubitemid 40647051)
9. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9:3991S-3994S. (Pubitemid 37169206)
10. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004;83:201-205. (Pubitemid 38443503)
11. Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemia in vitro and in vivo. Br J Haematol 2005;128:310-317. (Pubitemid 40216152)
12. Thomas DA, Faderl S, OBrien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
13. Stanciu-Herrera C, Morgan C, Herrera L. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemptherapy in pre-B acute lymphoblastic leukemia cell lines. Leuk Res 2008;32:625-632. (Pubitemid 351255553)
14. Chevallier P, Mahe B, Garand R, et al. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol 2008;88:209-211.
15. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009;23:806-807.
16. Dworzak MN, Schumich A, Printz D, et al. CD20 upregulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti- CD20 directed immunotherapy. Blood 2008;112:3982-3988.
17. Elia L, Mancini M, Moleti L, et al. A multiplex reverse trnscription-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Hematologica 2003;88:275-279. (Pubitemid 36361982)
18. Iyer SB, Hultin LE, Zawarzki JA, Davis KA, Giorgi JV. Quantitation of CD38 expression using QuantiBRITE beads. Cytometry 1998;33:206-212. (Pubitemid 28447145)
19. Davis KA, Abrams B, Iyer SB, Hoffman RA, Bishop JE. Determination of CD4 antigen density on cells:role of antibody valency, avidity, clones and conjugation. Cytometry 1998;33:197-205. (Pubitemid 28447144)
20. Morris ES, Vora A. Remission induction with single agent rituximab in a child with multiply relapsed precursor-B ALL. Br J Haematol 2007;139:344-346.
21. Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049-8057.
22. DArgouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-473.
23. Topp M, Zugmaier G, Goekbuget N, et al. CD19/CD3 bispecific antibody blinatumomab (MT-103) is highly effective in treatment of patients with minimal residual disease from chemotherapy-resistant B-precursor acute lymphoblastic leukemia. Blood 2010;116(Suppl. 1): Abstract 174.
24. Topp M, Goekbuget N, Kufer P, et al. Blinatumomab (anti-CD19 BITE1) for targeted therapy of minimal residual disease (MRD) in patients with b precursor acute lymphoblastic leukemia (ALL): update of an ongoing phase II study. Haematologica 2009;94(Suppl. 2): Abstract 0482.
25. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Childrens Oncology Group Pilot Study. J Clin Oncol 2008;26: 3756-3762.
26. Thomas DA, Cortes J, OBrien S, et al. Update of the modified Hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 2007;110(Suppl. 1): Abstract 2824.
27. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab in adult CD20 B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT. Haematologica 2009;94(Suppl. 2): Abstract 0481.
28. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20 B-lineage standard and high risk patients; results of 263 CD20 patients studied prospectively in GMALL study 07/2003. Blood 2010;116(Suppl. 1): Abstract 170.
29. Watt TC, Park S, Cooper T. CD20 up-regulation in induction therapy for childhood B lymphoblastic leukemia. Blood 2010;116(Suppl. 1): Abstract 2124.
30. Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010;78:147-153.
31. Vitale A, Guarini A, Ariola C, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Result of the GIMEMA ALL 0496 trial. Haematologica 2007;92: 342-348. (Pubitemid 350143543)
32. Cotter M, Rooney S, O'Marcaigh A, Smith OP. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br J Haematol 2003;122:686-691.
33. Zwaan CM, Reinhardt D, Jürgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003;17: 468-470. (Pubitemid 36277623)
34. Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001;15:406-414. (Pubitemid 32243774)